Empirical therapy for bacterial infections in neutropenic patients.
Infection in neutropenic patients remains a continuing challenge as the modalities of cancer treatment evolve and new pathogens appear. Although the concept of empirical therapy remains valid, there is a need for adaptation of our therapeutic approaches to new clinical and microbiological evidence.
Service de Médecine, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium.
J
J
Klastersky
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016207:Cytokines / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005334:Fever / Q000209:etiology; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D009181:Mycoses / Q000150:complications; D009369:Neoplasms / Q000150:complications; D009503:Neutropenia / Q000150:complications*; D014777:Virus Diseases / Q000150:complications
D000900:Anti-Bacterial Agents; D016207:Cytokines